NR 546 ADVANCED PHARMACOLOGY | CHAMBERLAIN
COLLEGE OF NURSING | ACADEMIC YEAR 2026/2027 |
WEEK 8
Important Disclaimer
This study guide does not contain actual Chamberlain University exam questions.
It provides original practice questions and content review to help you prepare
ethically for the NR 546 Week 8 Final Examination. Always follow your
institution's academic integrity policies and use official course resources for
preparation.
Core Domains
1. Alzheimer's Disease: Pathophysiology and Stages
2. Cholinesterase Inhibitors: Mechanisms and Clinical Use
3. NMDA Receptor Antagonists: Memantine and Neuroprotection
4. Behavioral and Psychological Symptoms of Dementia
5. ADHD: Pharmacologic Management Across the Lifespan
6. Substance Use Disorders: Pharmacotherapy and Withdrawal Management
7. Sleep-Wake Disorders: Pharmacologic Interventions
8. Neurotransmitter Systems and Drug Mechanisms
9. Special Populations: Geriatric and Pediatric Considerations
10. Ethical and Legal Considerations in Psychopharmacology
Introduction
This comprehensive examination assesses mastery of advanced
psychopharmacology principles for the psychiatric-mental health nurse
practitioner. The examination evaluates Alzheimer's disease pathophysiology and
treatment, cholinesterase inhibitors, NMDA receptor antagonists, behavioral
,symptoms of dementia, ADHD pharmacotherapy, substance use disorder
treatment, sleep disorder management, and neurotransmitter systems. Questions
are structured in multiple-choice and scenario-based formats to simulate real-
world clinical decision-making. Emphasis is placed on applying evidence-based
practice, demonstrating critical thinking, and exercising professional judgment in
psychopharmacologic management. This assessment prepares candidates for the
NR 546 Week 8 Final Examination.
Question 1
A 72-year-old patient is diagnosed with mild Alzheimer's disease. The PMHNP
understands that the primary pathophysiological hallmarks of Alzheimer's disease
include which of the following?
A. Dopamine depletion in the substantia nigra
B. Amyloid-beta plaques and tau neurofibrillary tangles
C. Demyelination of axons in the central nervous system
D. Serotonin deficiency in the raphe nuclei
B. Amyloid-beta plaques and tau neurofibrillary tangles
RATIONALE: Alzheimer's disease is characterized by two primary pathological
hallmarks: extracellular amyloid-beta plaques and intracellular tau neurofibrillary
tangles. These abnormalities lead to progressive neuronal loss, synaptic
dysfunction, and brain atrophy, particularly in the hippocampus and cortex, which
are critical for memory and cognitive function. Option A describes Parkinson's
disease. Option C describes multiple sclerosis. Option D describes a
neurotransmitter deficiency associated with depression, not AD pathology.
Question 2
A PMHNP is initiating pharmacotherapy for a 68-year-old patient with moderate
Alzheimer's disease. Which medication is considered first-line for cognitive
symptom management?
, A. Sertraline
B. Donepezil
C. Quetiapine
D. Lorazepam
B. Donepezil
RATIONALE: Cholinesterase inhibitors, including donepezil, rivastigmine, and
galantamine, are first-line pharmacologic treatments for mild to moderate
Alzheimer's disease. They work by inhibiting acetylcholinesterase, thereby
increasing acetylcholine levels in the synaptic cleft and temporarily improving
cognitive function. Sertraline is an SSRI used for depression. Quetiapine is an
atypical antipsychotic used for behavioral symptoms. Lorazepam is a
benzodiazepine, which should be avoided in older adults due to increased fall and
confusion risk.
Question 3
A 70-year-old patient with Alzheimer's disease is prescribed donepezil. The
PMHNP should educate the patient and family that which of the following is the
most common adverse effect of cholinesterase inhibitors?
A. Hypertension and tachycardia
B. Gastrointestinal symptoms including nausea and diarrhea
C. Weight gain and sedation
D. Bradycardia and bronchospasm
B. Gastrointestinal symptoms including nausea and diarrhea
RATIONALE: The most common adverse effects of cholinesterase inhibitors
are gastrointestinal, including nausea, diarrhea, vomiting, and anorexia. These
effects are due to increased cholinergic activity in the GI tract. To minimize GI
upset, donepezil is typically taken at bedtime. Other potential effects include
bradycardia, vivid dreams, and muscle cramps. Options A, C, and D do not
accurately describe the most common adverse effect profile.
COLLEGE OF NURSING | ACADEMIC YEAR 2026/2027 |
WEEK 8
Important Disclaimer
This study guide does not contain actual Chamberlain University exam questions.
It provides original practice questions and content review to help you prepare
ethically for the NR 546 Week 8 Final Examination. Always follow your
institution's academic integrity policies and use official course resources for
preparation.
Core Domains
1. Alzheimer's Disease: Pathophysiology and Stages
2. Cholinesterase Inhibitors: Mechanisms and Clinical Use
3. NMDA Receptor Antagonists: Memantine and Neuroprotection
4. Behavioral and Psychological Symptoms of Dementia
5. ADHD: Pharmacologic Management Across the Lifespan
6. Substance Use Disorders: Pharmacotherapy and Withdrawal Management
7. Sleep-Wake Disorders: Pharmacologic Interventions
8. Neurotransmitter Systems and Drug Mechanisms
9. Special Populations: Geriatric and Pediatric Considerations
10. Ethical and Legal Considerations in Psychopharmacology
Introduction
This comprehensive examination assesses mastery of advanced
psychopharmacology principles for the psychiatric-mental health nurse
practitioner. The examination evaluates Alzheimer's disease pathophysiology and
treatment, cholinesterase inhibitors, NMDA receptor antagonists, behavioral
,symptoms of dementia, ADHD pharmacotherapy, substance use disorder
treatment, sleep disorder management, and neurotransmitter systems. Questions
are structured in multiple-choice and scenario-based formats to simulate real-
world clinical decision-making. Emphasis is placed on applying evidence-based
practice, demonstrating critical thinking, and exercising professional judgment in
psychopharmacologic management. This assessment prepares candidates for the
NR 546 Week 8 Final Examination.
Question 1
A 72-year-old patient is diagnosed with mild Alzheimer's disease. The PMHNP
understands that the primary pathophysiological hallmarks of Alzheimer's disease
include which of the following?
A. Dopamine depletion in the substantia nigra
B. Amyloid-beta plaques and tau neurofibrillary tangles
C. Demyelination of axons in the central nervous system
D. Serotonin deficiency in the raphe nuclei
B. Amyloid-beta plaques and tau neurofibrillary tangles
RATIONALE: Alzheimer's disease is characterized by two primary pathological
hallmarks: extracellular amyloid-beta plaques and intracellular tau neurofibrillary
tangles. These abnormalities lead to progressive neuronal loss, synaptic
dysfunction, and brain atrophy, particularly in the hippocampus and cortex, which
are critical for memory and cognitive function. Option A describes Parkinson's
disease. Option C describes multiple sclerosis. Option D describes a
neurotransmitter deficiency associated with depression, not AD pathology.
Question 2
A PMHNP is initiating pharmacotherapy for a 68-year-old patient with moderate
Alzheimer's disease. Which medication is considered first-line for cognitive
symptom management?
, A. Sertraline
B. Donepezil
C. Quetiapine
D. Lorazepam
B. Donepezil
RATIONALE: Cholinesterase inhibitors, including donepezil, rivastigmine, and
galantamine, are first-line pharmacologic treatments for mild to moderate
Alzheimer's disease. They work by inhibiting acetylcholinesterase, thereby
increasing acetylcholine levels in the synaptic cleft and temporarily improving
cognitive function. Sertraline is an SSRI used for depression. Quetiapine is an
atypical antipsychotic used for behavioral symptoms. Lorazepam is a
benzodiazepine, which should be avoided in older adults due to increased fall and
confusion risk.
Question 3
A 70-year-old patient with Alzheimer's disease is prescribed donepezil. The
PMHNP should educate the patient and family that which of the following is the
most common adverse effect of cholinesterase inhibitors?
A. Hypertension and tachycardia
B. Gastrointestinal symptoms including nausea and diarrhea
C. Weight gain and sedation
D. Bradycardia and bronchospasm
B. Gastrointestinal symptoms including nausea and diarrhea
RATIONALE: The most common adverse effects of cholinesterase inhibitors
are gastrointestinal, including nausea, diarrhea, vomiting, and anorexia. These
effects are due to increased cholinergic activity in the GI tract. To minimize GI
upset, donepezil is typically taken at bedtime. Other potential effects include
bradycardia, vivid dreams, and muscle cramps. Options A, C, and D do not
accurately describe the most common adverse effect profile.
